Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494233 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
A Phase 2 study of Irritable Bowel Syndrome, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 373
- Enrollment target
- 20
- Study locations
NCT01494233: Completed Phase 2 study of Irritable Bowel Syndrome, sponsored by Lexicon Pharmaceuticals.
NCT01494233 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 373 participants, above the 136-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (174% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494233, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 373 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
Conditions Studied
Interventions
- DRUG Placebo tablet
- DRUG 250 mg LX1033 tablets
Study Locations (20)
California
- Lexicon Investigational Site - Anaheim
- Lexicon Investigational Site - Encinitas
- Lexicon Investigational Site - Los Angeles
- Lexicon Investigational Site - Oakland
- Lexicon Investigational Site - Orange
- Lexicon Investigational Site - San Diego
- Lexicon Investigational Site - Santa Monica
- Lexicon Investigational Site - Tustin
- Lexicon Investigational Site - Westlake Village
Arizona
- Lexicon Investigational Site - Tempe
- Lexicon Investigational Site - Tucson
- Lexicon Investigational Site - Tucson
Colorado
- Lexicon Investigational Site - Littleton
- Lexicon Investigational Site - Littleton
- Lexicon Investigational Site - Wheat Ridge
Arkansas
- Lexicon Investigational Site - Little Rock
- Lexicon Investigational Site - North Little Rock
Alabama
- Lexicon Investigational Site - Huntsville
Connecticut
- Lexicon Investigational Site - Waterbury
Florida
- Lexicon Investigational Site - Boynton Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01494233 record still lists
NCT01494233 is an interventional study that assigns participants to a tested intervention. The registered 373 participants enrollment target is mid-sized for trials with a published cap, above the 136-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (174% higher).
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo tablet is the first listed.
NCT01494233 names 20 study sites across 7 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT01494233 about?
NCT01494233 is a clinical study titled "A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome". The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
What is the current status of trial NCT01494233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2012-02.
What conditions does trial NCT01494233 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01494233?
The interventions under investigation include: Placebo tablet (DRUG), 250 mg LX1033 tablets (DRUG).
Who is sponsoring clinical trial NCT01494233?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01494233 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01494233's enrollment target sits among peer trials
373 5th of 47 higher than 43 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
RECRUITING · Phase 2
-
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · Phase 2
-
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
COMPLETED · Phase 2
-
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07276750 · 373 participants · NA
Coaching and Leadership in Autism Support Settings
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia